These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8709389)

  • 21. From the Centers for Disease Control. FDA approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine.
    JAMA; 1992 Jan 22-29; 267(4):485. PubMed ID: 1729566
    [No Abstract]   [Full Text] [Related]  

  • 22. From the Centers for Disease Control. FDA approval of second diphtheria, tetanus toxoids, and acellular pertussis vaccine.
    JAMA; 1992 Oct; 268(14):1834, 1837. PubMed ID: 1404700
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of pertussis vaccines: US Food and Drug Administration regulatory considerations.
    Farizo KM; Burns DL; Finn TM; Gruber MF; Pratt RD
    J Infect Dis; 2014 Apr; 209 Suppl 1():S28-31. PubMed ID: 24626869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From the Centers for Disease Control and Prevention. FDA approval of a second acellular pertussis vaccine for use among infants and young children.
    JAMA; 1997 Mar; 277(10):783. PubMed ID: 9052694
    [No Abstract]   [Full Text] [Related]  

  • 31. Diphtheria, tetanus, and pertussis: guidelines for vaccine prophylaxis and other preventive measures. Recommendation of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):896-905. PubMed ID: 2998252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pertussis vaccination with acellular vaccines. Tolerance--effectiveness--current vaccination recommendations].
    Liese JG; Stojanov S; Belohradsky BH
    Fortschr Med; 1997 Aug; 115(24):22-7. PubMed ID: 9410815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model.
    Mansour M; Brown RG; Morris A; Smith B; Halperin SA
    Clin Vaccine Immunol; 2007 Oct; 14(10):1381-3. PubMed ID: 17715327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult immunization with acellular pertussis vaccine.
    Edwards KM; Decker MD; Graham BS; Mezzatesta J; Scott J; Hackell J
    JAMA; 1993 Jan; 269(1):53-6. PubMed ID: 8416406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Answers to questions about the acellular pertussis vaccine.
    Kimmel SR
    Am Fam Physician; 1993 Jun; 47(8):1825-32. PubMed ID: 8498289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Apr; 42(15):296-8. PubMed ID: 8479415
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
    Langue J; Matisse N; Pacoret P; Undreiner F; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1406-14. PubMed ID: 15063563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.